FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Vashington,	DС	20549	
vasilington,	D.C.	20049	

STATEMENT OF CHANGES IN BENEFICIAL OWNERSH	ΗP
--	----

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* <u>Vivaldi Coelho Rogerio</u>					2. Issuer Name and Ticker or Trading Symbol Crinetics Pharmaceuticals, Inc. [CRNX]							ck all applica	,				
	NETICS PI	irst) HARMACEUTI			3. Date of Earliest Transaction (Month/Day/Year) 01/03/2022								Officer (below)	give title		Other (sp below)	pecify
10222 BARNES CANYON ROAD, BLDG 2					4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Individual or Joint/Group Filing (Check Applicable						
(Street) SAN DII	EGO C	A	92121		01/10/2022						Line)	·					
(City)	(S	tate)	(Zip)														
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
1. Title of Security (Instr. 3) 2. Transc Date (Month/L			•	Execution Date,		Code (Instr.			and 5) Securities Beneficially Owned Foll		Form:	Direct Indirect B	7. Nature of ndirect Beneficial Ownership				
								Code	v	Amount	(A) or (D)	Price	Reported Transactio (Instr. 3 ar	on(s)		"	nstr. 4)
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	rivative Conversion Date Execution Date, Transacticurity or Exercise (Month/Day/Year) if any Code (Ins						ies g Derivative	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	lly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)					
					v	(A)	(D)	Date Exercisable		xpiration ate	Title	Amount or Number of Shares		(Instr. 4)	on(s)		
Stock Option (right to buy)	\$28.31	01/03/2022		A		35,000 ⁽¹⁾		(2)	12	2/31/2031	Common Stock	35,000(1)	\$0.00	35,000 ⁽	(1)	D	

Explanation of Responses:

- 1. On January 10, 2022, the reporting person filed a Form 4 which inadvertently reported that he was granted an option to purchase 25,000 shares of the issuer's common stock. In fact, as reported in this amendment, the reporting person was granted an option to purchase 35,000 shares of common stock.
- 2. The option shall vest and become exercisable in three substantially equal annual installments on each of the first three anniversaries of the date of grant, subject to continued service as a director through each such

Remarks:

/s/ Marc Wilson, as attorney-in-

04/04/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.